Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGH447 + BYL719 in Relapsed/Refractory Multiple Myeloma
NCT02144038Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of PIM447 in multiple myeloma (MM) (3 arms), sponsored by Novartis. Primary endpoints: Dose-limiting Toxicities and Overall Response Rate at 29 months. Started Jul 2014; status: completed.
02
Drugs
PIM447
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02144038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144038.